Pittsburgh, PANCT01720836Now EnrollingIRB Ready

Non-small Cell Lung Cancer (NSCLC) Clinical Trial in Pittsburgh, PA

Access cutting-edge non-small cell lung cancer (nsclc) treatment through this phase 1/2 clinical trial at a research site in Pittsburgh. Study-provided care at no cost to qualified participants.

Sponsored by Olivera Finn

Quick Self-Assessment

See if you qualify for this Pittsburgh location

Preparing your pre-screening questions…

Expert Care in Pittsburgh

Access non-small cell lung cancer (nsclc) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related non-small cell lung cancer (nsclc) treatment provided free

Apply for This Pittsburgh Location

Check if you qualify for this non-small cell lung cancer (nsclc) clinical trial in Pittsburgh, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Pittsburgh

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Pittsburgh site if eligible
  4. 4Begin participation

About This Non-small Cell Lung Cancer (NSCLC) Study in Pittsburgh

All subjects will receive the vaccine subcutaneously every 3 weeks x 3 with optional yearly booster vaccines up to and including 5 years post last vaccine for those patients who are confirmed responders to the vaccine . The rationale for using Poly-ICLC as an adjuvant are two ongoing trials at University of Pittsburgh Cancer Institute (UPCI) of the MUC1 100mer peptide vaccine - one as a therapeutic vaccine in subjects with metastatic castrate resistant prostate cancer and the other in subjects with advanced colonic adenomas at risk for developing colon cancer. The same formulation, MUC1 100mer peptide admixed with Poly-ICLC, is used in both trials. There has been no toxicity observed and the vaccine is highly immunogenic in early disease. In the proposed NSCLC trial the anti-MUC1 immune response will be thoroughly characterized.

Sponsor: Olivera Finn

Who Can Participate

Inclusion Criteria

Subjects must have histologically or cytologically confirmed non-small cell lung cancer (NSCLC) or neuroendocrine carcinoid tumor
All subjects must have one of the following stages: Stage IA(T1NO); IB (T2NO), II \& IIIA (N2 negative); IIIA (N2+), IIIB (N3+)
Patients must have stable disease at the time of enrollment
Women and men at least 18 years of age
ECOG performance status 0-1(Appendix A)
Subjects must be within 4 to 24 weeks of standard of care treatment for their particular stage of disease
Subjects must have acceptable organ and marrow function as defined below:
Leukocytes \> 3,000/µL
Absolute Neutrophils \> 1,500/µL
Hemoglobin \> 10 g/dL
Platelets \> 100,000/µL
Total Bilirubin within normal institutional limits
Creatinine within normal institutional limits OR
Creatinine clearance \> 60 mL/min/1.73 m2 for subjects with above normal AST and ALT with alkaline phosphatase within \< 1.5 times upper limit of normal
The effects of a MUC1vaccine on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, men and women of childbearing potential must be willing to use effective contraception (hormonal barrier method of birth control; abstinence) while on study treatment and for at least 3 months thereafter. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately

Exclusion Criteria

Subjects may not be receiving any other investigational agents \- No history of prior malignancy, except for non-melanoma skin cancer
Any positive ANA titer above 1:160, even in an asymptomatic individual. Note: Weakly positive ANA defined as ANA titers up to 1:160 maximum (≤ 1:160) will be acceptable in an asymptomatic individual who is otherwise eligible for the study.
Known Hepatitis B on immunomodulators (i.e. interferon)
Known Hepatitis C on immunomodulators (i.e. interferon)
No prior vaccine therapy
Patients may not be receiving any steroids or other anti-immune therapy at the time of registration.
Subjects must not be more than 24 weeks from standard of care treatment for their particular stage of disease
Subjects must not have post-obstructive pneumonia or other serious infection at the time of registration or other serious underlying medical condition that would impair the ability of the subjects to receive protocol treatment
Prior resection of lung cancer is allowed, if at least five years have elapsed between previous resection and registration
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Pregnant women are excluded from this study. Women of childbearing potential must have a negative pregnancy test
Subjects with immune deficiency are not expected to respond to the vaccine. Therefore, known HIV-positive patients are excluded from the study
Subjects with a history of known autoimmune disease are excluded from this study

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Pittsburgh?

Yes, this clinical trial (NCT01720836) has an active research site in Pittsburgh, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Non-small Cell Lung Cancer (NSCLC) Treatment Options in Pittsburgh, PA

If you're searching for non-small cell lung cancer (nsclc) treatment options in Pittsburgh, PA, this clinical trial (NCT01720836) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Pittsburgh research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced non-small cell lung cancer (nsclc) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all non-small cell lung cancer (nsclc) clinical trials near you to find additional studies recruiting in your area.

More Lung Cancer Trials in Pittsburgh, PA

See all lung cancer clinical trials recruiting in Pittsburgh — not just this study.

Browse Lung Cancer Trials in Pittsburgh →

Browse More Trials by Condition

Lung Cancer TrialsLeukemia TrialsSmall Cell Lung Cancer TrialsNon-Small Cell Lung Cancer TrialsSpinal Muscular Atrophy TrialsAll Conditions →

Ready to Join in Pittsburgh?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Pittsburgh, PA